NYSEARCA:SCPX • US42237K5083
The current stock price of SCPX is 0.068 USD. In the past month the price decreased by -59.04%. In the past year, price decreased by -78.97%.
ChartMill assigns a fundamental rating of 2 / 10 to SCPX. SCPX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SCPX reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by 20.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.96% | ||
| ROE | -128.83% | ||
| Debt/Equity | 0.31 |
7 analysts have analysed SCPX and the average price target is 5.1 USD. This implies a price increase of 7400% is expected in the next year compared to the current price of 0.068.
For the next year, analysts expect an EPS growth of 97.7% and a revenue growth 63.27% for SCPX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
SCORPIUS HOLDINGS INC
1305 E. Houston Street, Building 2
San Antonio TEXAS US
Employees: 83
Phone: 19192407133
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in San Antonio, Texas and currently employs 82 full-time employees. The company went IPO on 2013-07-24. The firm couples Current Good Manufacturing Practices (CGMP) biomanufacturing and quality control knowledge with capabilities in immunoassays, molecular assays, and bioanalytical methods to support cell- and gene-based therapies as well as large molecule biologics using American-made equipment, reagents, and materials. The company offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. The firm's CDMO service offerings also include enhanced microbial and mammalian development and manufacturing services.
The current stock price of SCPX is 0.068 USD. The price decreased by -48.48% in the last trading session.
SCPX does not pay a dividend.
SCPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SCPX stock is listed on the NYSE Arca exchange.
SCORPIUS HOLDINGS INC (SCPX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCPX.